[1]江 瑜,王敏娟,李亚军.烟雾病的发病机制、诊断和治疗研究[J].医学信息,2021,34(08):41-44,49.[doi:10.3969/j.issn.1006-1959.2021.08.011]
 JIANG Yu,WANG Min-juan,LI Ya-jun.Research on the Pathogenesis,Diagnosis and Treatment of Moyamoya Disease[J].Medical Information,2021,34(08):41-44,49.[doi:10.3969/j.issn.1006-1959.2021.08.011]
点击复制

烟雾病的发病机制、诊断和治疗研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年08期
页码:
41-44,49
栏目:
综述
出版日期:
2021-04-15

文章信息/Info

Title:
Research on the Pathogenesis,Diagnosis and Treatment of Moyamoya Disease
文章编号:
1006-1959(2021)08-0041-05
作者:
江 瑜王敏娟李亚军
(西安医学院第一附属医院,陕西 西安 710000)
Author(s):
JIANG YuWANG Min-juanLI Ya-jun
(The First Affiliated Hospital of Xi’an Medical University,Xi’an 710000,Shaanxi,China)
关键词:
烟雾病脑血管造影癫痫
Keywords:
Moyamoya diseaseCerebral angiographyEpilepsy
分类号:
R743
DOI:
10.3969/j.issn.1006-1959.2021.08.011
文献标志码:
A
摘要:
烟雾病(MMD)的病因及发病机制不明,其临床表现为缺血性或出血性卒中、头痛、癫痫或短暂性脑缺血发作。脑血管造影是诊断MMD的最佳方法,但随着技术的进步,非侵入性技术越来越多地被用于准确评价MMD。外科手术作为MMD的治疗方法,其疗效确切,但最佳手术方式尚无定论。本文就MMD的流行病学、发病机制、诊断、临床特征、治疗作一综述,旨在为临床治疗该疾病提供参考依据。
Abstract:
The etiology and pathogenesis of Moyamoya disease (MMD) are unknown, and its clinical manifestations are ischemic or hemorrhagic stroke, headache, epilepsy, or transient ischemic attack.Cerebral angiography is the best method to diagnose MMD, but with the advancement of technology, non-invasive techniques are increasingly used to accurately evaluate MMD.Surgery, as a treatment method for MMD, has a definite effect, but the best surgical method is still inconclusive.This article reviews the epidemiology, pathogenesis, diagnosis, clinical features, and treatment of MMD, aiming to provide a reference for the clinical treatment of the disease.

参考文献/References:

[1]Takeuchi K,Shimizu K.Hypogenesis of bilateral internal carotid arteries[J].No Ta Shinkai,1957(9):37-43. [2]Suzuki J,Takaku A.Cerebrovascular’moyamoya’disease.Disease showing abnormal net-like vessels in base of brain[J].Archives of Neurology,1969,20(3):288-299. [3]Ikezaki K,Inamura T,Kawano T,et al.Clinical features of probable moyamoya disease in Japan[J].Clinical Neurology and Neurosurgery,1997,99(2):170-174. [4]Baba T,Houkin K,Kuroda S.Novel epidemiological features of moyamoya disease[J].J Neurol Neurosurg Psychiatry,2008,79(8):900-904. [5]Porras JL,Yang W,Xu R,et al.Effectiveness of Ipsilateral Stroke Prevention Between Conservative Management and Indirect Revascularization for Moyamoya Disease in a North American Cohort[J].World Neurosurg,2018(110):e928-e936. [6]Kainth D,Chaudhry SA,Kainth H,et al.Epidemiological and clinical features of moyamoya disease in the USA[J].Neuroepidemiology,2013,40(4):282-287. [7]Ahn IM,Park DH,Hann HJ,et al.Incidence,prevalence,and survival of moyamoya disease in Korea:a nationwide,population-based study[J].Stroke,2014,45(4):1090-1095. [8]Miao W,Zhao PL,Zhang YS,et al.Epidemiological and clinical features of Moyamoya disease in Nanjing,China[J].Clin Neurol Neurosurg,2010,112(3):199-203. [9]赵庆顺.基于改良suzuki分期的成人烟雾病患者脑血流特点及临床意义[D].南方医科大学,2018. [10]Acker G,Goerdes S,Schneider UC,et al.Distinct clinical and radiographic characteristics of moyamoya disease amongst European Caucasians[J].Eur J Neurol,2015,22(6):1012-1017. [11]Lin J,Sheng W.RNF213 Variant Diversity Predisposes Distinct Populations to Dissimilar Cerebrovascular Diseases[J].Biomed Res Int,2018(2018):6359174. [12]Liu W,Morito D,Takashima S,et al.Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development[J].PLoS One,2011,6(7):1-20. [13]Choi EH,Lee H,Chung JW,et al.Ring Finger Protein 213 Variant and Plaque Characteristics,Vascular Remodeling, and Hemodynamics in Patients With Intracranial Atherosclerotic Stroke:A High-Resolution Magnetic Resonance Imaging and Hemodynamic Study[J].J Am Heart Assoc,2019,8(20):e011996. [14]Tashiro R,Fujimura M,Sakata H,et al.Genetic analysis of ring finger protein 213(RNF213)c.14576G>A polymorphism in patients with vertebral artery dissection:a comparative study with moyamoya disease[J].Neurol Res,2019,41(9):811-816. [15]Zhang Q,Liu Y,Yu L,et al.The Association of the RNF213 p.R4810K Polymorphism with Quasi-Moyamoya Disease and a Review of the Pertinent Literature[J].World Neurosurg,2017(99):701-708.e1. [16]Wu Z,Jiang H,Zhang L et al.Molecular analysis of RNF213 gene for Moyamoya disease in the Chinese Han population[J].PLoS One,2012,7(10):e48179. [17]Koizumi A,Kobayashi H,Hitomi T,et al.A new horizon of moyamoya disease and associated health risks explored through RNF213[J].Environ Health Prev Med,2016,21(2):55-70. [18]Kim EH,Yum MS,Ra YS,et al.Importance of RNF213 polymorphism on clinical features and long-term outcome in moyamoya disease[J].J Neurosurg,2016,124(5):1221-1227. [19]Jang MA,Chung JW,Yeon JY,et al.Frequency and significance of rare RNF213 variants in patients with adult moyamoya disease[J].PLoS One,2017,12(6):e0179689. [20]Sonobe S,Fujimura M,Niizuma K,et al.Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213:a susceptibility gene for moyamoya disease[J].Brain Res,2014(1552):64-71. [21]黄燕兰,程道宾,张皆德,等.RNF213基因多态性与广西壮族成人烟雾病遗传易感性研究[J].中风与神经疾病杂志,2015,32(10):918-921. [22]申伟,李劲松,李伟,等.免疫相关蛋白在烟雾病患者硬脑膜血管壁中的表达[J].中国脑血管病杂志,2013,10(4):174-177. [23]Tashiro R,Niizuma K,Khor SS,et al.Identification of HLA-DRB1*04:10 allele as risk allele for Japanese moyamoya disease and its association with autoimmune thyroid disease:A case-control study[J].PLoS One,2019,14(8):e0220858. [24]姜婉.中国汉族人烟雾病的HLA风险区域关联研究及HDAC9基因多态性的研究[D].安徽医科大学,2019. [25]王荪蔚.外周调节性T细胞及Th17细胞与烟雾病的相关性的研究[D].南京大学,2016. [26]Zhang JJ,Xiong ZW,Wang S,et al.Significance of cyclooxygenase-2 elevation in middle cerebral artery for patients with hemorrhagic moyamoya disease[J].J Huazhong Univ Sci Technolog Med Sci,2016,36(2):181-185. [27]章剑剑.IL-1β诱导烟雾病患者颅内血管壁上COX-2/mPGES-1的表达在烟雾病进展中的可能机制探讨[D].华中科技大学,2015. [28]Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis;Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases.Guidelines for diagnosis and treatment of moyamoya disease(spontaneous occlusion of the circle of Willis)[J].Neurol Med Chir(Tokyo),2012,52(5):245-266. [29]Gaillard J,Klein J,Duran D,et al.Incidence,clinical features,and treatment of familial moyamoya in pediatric patients:a single-institution series[J].J Neurosurg Pediatr,2017,19(5):553-559. [30]孙玮良,赵黎明,梁浩,等.烟雾病的临床特征及外科治疗的流行病学分析[J].中国实用神经疾病杂志,2020,23(6):485-490. [31]Sato Y,Kazumata K,Nakatani E,et al.Characteristics of Moyamoya Disease Based on National Registry Data in Japan[J].Stroke,2019,50(8):1973-1980. [32]Kraemer M,Berlit P,Diesner F,et al.What is the expert’s option on antiplatelet therapy in moyamoya disease?Results of a worldwide Survey[J].Eur J Neurol,2012,19(1):163-167. [33]Yamada S,Oki K,Itoh Y,et al.Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of research committee on moyamoya disease in japan[J].J Stroke Cerebrovasc Dis,2016,25(2):340-349. [34]Onozuka D,Hagihara A,Nishimura K,et al.Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease:a nationwide retrospective cohort study(J-ASPECT study)[J].BMJ Open,2016,6(3):e009942. [35]Zhao Y,Zhang Q,Zhang D,et al.Effect of aspirin in postop-erative management of adult ischemic moyamoya disease[J].World Neurosurg,2017(105):728-731. [36]烟雾病和烟雾综合征诊断与治疗中国专家共识编写组国家卫生计生委脑卒中防治专家委员会缺血性卒中外科专业委员会.烟雾病和烟雾综合征诊断与治疗中国专家共识(2017)[J].中华神经外科杂志,2017,33(6):541-547. [37]Kuroda S,Houkin K.Bypass surgery for moyamoya disease[J].Neurol Med Chir(Tokyo),2012,52(5):287-294. [38]Hori S,Acker G,Vajkoczy P.Radial artery grafts as rescue strategy for patients with moyamoya disease for whom conventional revascu-larization failed[J].World Neurosurg,2016(5):77-84. [39]Teo M,Johnson J,Steinberg GK.Strategies for and outcome of repeat revascularization surgery for moyamoya disease:an American Institutional Series[J].Neurosurgery,2017(81):852-859. [40]Miyamoto S,Yoshimoto T,Hashimoto,et al.Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease:results of the Japan Adult Moyamoya Trial[J].Stroke,2014(45):1415-1421. [41]Zhang M,Raynald,Zhang D,et al.Combined STA-MCA Bypass and Encephalodurosynangiosis Versus Encephalodurosynangiosis Alone in Adult Hemorrhagic Moyamoya Disease:A 5 -Year Outcome Study[J].J Stroke Cerebrovasc Dis,2020,29(6):104811. [42]Zhang Q,Zhang D,Wang R,et al.Clinical and Angiographic Features of Patients with Moyamoya Disease and the p.R4810K Heterozygous Variant[J].World Neurosurg,2016(90):530-538.e3. [43]Gadgil N,Lam S,Pyarali M,et al.Indirect revascularization with the dural inversion technique for pediatric moyamoya disease:20-year experience[J].J Neurosurg Pediatr,2018,22(5):541-549. [44]Cho WS,Kim JE,Kim CH,et al.Long-term outcomes after combined revascularization surgery in adult moyamoya disease[J].Stroke,2014,45(10):025-3031. [45]Aoun RJ,Zammar SG,Hamade YJ,et al.Combined direct and indirect revascu-larization is associated with low rates of recurrent ischemic and hemorrhagic stroke in adult moyamoya disease[J].Neurosurgery,2015,76(4):15-16. [46]Uchino H,Kim JH,Fujima N,et al.Synergistic Interactions Between Direct and Indirect Bypasses in Combined Procedures:The Significance of Indirect Bypasses in Moyamoya Disease[J].Neurosurgery,2017,80(2):201-209. [47]Macyszyn L,Attiah M,Ma TS,et al.Direct versus indirect revascularization procedures for moyamoya disease:a comparative effectiveness study[J].J Neurosurg,2017,126(5):1523-1529. [48]Fujimura M,Mugikura S,Kaneta T,et al.Incidence and risk factors for symptomatic cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease[J].Surg Neurol,2009,71(4):442-447. [49]Mukerji N,Cook DJ,Steinberg GK.Is local hypoper-fusion the reason for transient neurological deficits after STA-MCA bypass for moyamoya disease[J].J Neurosurg,2015,122(1):90-94.

相似文献/References:

[1]吴文菁,邓克学.成人出血型与缺血型烟雾病的3D pCASL侧支分布特点比较[J].医学信息,2021,34(08):170.[doi:10.3969/j.issn.1006-1959.2021.08.047]
 WU Wen-jing,DENG Ke-xue.Comparison of 3D pCASL Collateral Distribution Characteristics Between Adult Hemorrhagic and Ischemic Moyamoya Disease[J].Medical Information,2021,34(08):170.[doi:10.3969/j.issn.1006-1959.2021.08.047]

更新日期/Last Update: 1900-01-01